Nanomedicine Nanotechnology Biology and Medicine · 2019 · 38 citations · 31 references
PharmacyPharmaceuticsPharmacokineticsDrug DeliveryTargeted Drug DeliveryTheranosticsNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle CharacterizationNanoparticle DesignTheranostic NanoparticlesActivated Hepatic Stellate CellsEarly DiagnosisHepatic Stellate Cell BiologyHepatic Stellate Cell DistributionIron Oxide NanoparticlesNanoparticle DeliveryOff-target Tissue EffectsTheranostic Nanomedicine
Hepatic cirrhosis is a growing health problem with increasing mortality worldwide. So far, there is a lack of early diagnosis and no clinical therapy is approved for the treatment. In this study, we developed a novel theranostic nanomedicine by targeting relaxin (RLX) that is known to possess potent anti-fibrotic properties but simultaneously has poor pharmacokinetics and detrimental off-target effects. We conjugated RLX to PEGylated superparamagnetic iron-oxide nanoparticles (RLX-SPIONs) and examined hepatic stellate cells (HSCs) specific binding/uptake. Thereafter, we assessed the therapeutic efficacy of RLX-SPIONs on human HSCs in vitro and in vivo in CCl4-induced liver cirrhosis mouse model. RLX-SPIONs showed specific binding and uptake in TGFβ-activated HSCs, and inhibited TGFβ-induced HSCs differentiation, migration and contraction. In vivo, RLX-SPIONs strongly attenuated cirrhosis and showed enhanced contrast in MR imaging. Altogether, this study presents RLX-SPIONs as a novel theranostic nanomedicine that provides new opportunities for the diagnosis and treatment of liver cirrhosis.
31
Relaxin Reverses Cardiac and Renal Fibrosis in Spontaneously Hypertensive Rats
Edna D. Lekgabe, Helen Kiriazis, Chongxin Zhao et al. · Hypertension · 2005 · 200 citations · Full text
Medicine, Pharmacology, Physiology +17